Dissecting the inflammatory tumor microenvironment of esophageal adenocarcinoma: mast cells and natural killer cells are favorable prognostic factors and associated with less extensive disease

被引:4
作者
Cunha, Alyne Conduru dos Santos [1 ]
Simon, Adrian Georg [1 ]
Zander, Thomas [3 ]
Buettner, Reinhard [1 ]
Bruns, Christiane Josephine [2 ]
Schroeder, Wolfgang [2 ]
Gebauer, Florian [2 ]
Quaas, Alexander [1 ]
机构
[1] Univ Cologne, Univ Hosp Cologne, Inst Pathol, Med Fac, Kerpener Str 62, DE-50937 Cologne, Germany
[2] Univ Cologne, Univ Hosp Cologne, Med Fac, Dept Gen Visceral & Canc Surg, Cologne, Germany
[3] Univ Cologne, Univ Hosp Cologne, Med Fac, Dept Internal Med 1, Cologne, Germany
关键词
Esophageal cancer; Esophageal adenocarcinoma; Mast cells; Tumor microenvironment; Natural killer cells; Tumor immune environment; PLASMA-CELLS; CANCER; SURVIVAL; EPIDEMIOLOGY; CARCINOMA; DIAGNOSIS; DENSITY; ROLES;
D O I
10.1007/s00432-023-04650-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PurposeEsophageal adenocarcinoma (EAC) remains a challenging and lethal cancer entity. A promising target for new therapeutic approaches, as demonstrated by the success of immune checkpoint inhibitors, are tumor-associated immune cells and the tumor microenvironment (TME). However, the understanding of the TME in esophageal cancer remains limited and requires further investigation.MethodsOver 900 EAC samples were included, including patients treated with primary surgery and neoadjuvant (radio-)chemotherapy. The immune cell infiltrates of mast cells (MC), natural killer cells (NK cells), plasma cells (PC), and eosinophilic cells (EC) were assessed semi-quantitatively and correlated with histopathological parameters and overall survival (OS).ResultsA high presence of all four immune cell types significantly correlated with a less extensive tumor stage and a lower frequency of lymph node metastasis, and, in case of NK cells, with less distant metastasis. The presence of MC and NK cells was favorably associated with a prolonged OS in the total cohort (MC: p < 0.001; NK cells: p = 0.004) and patients without neoadjuvant treatment (MC: p < 0.001; NK cells: p = 0.01). NK cells were a favorable prognostic factor in the total cohort (p = 0.007) and in the treatment-naive subgroup (p = 0.04). Additionally, MC were a favorable prognostic factor in patients with lymph node metastasis (p = 0.009).ConclusionOur results indicate a complex and important role of mast cells, NK cells, and the other assessed immune cells in the tumor microenvironment of EAC. Therefore, they are one further step to a better understanding of the immune cell environment and the potential therapeutic implications in this cancer entity.
引用
收藏
页码:6917 / 6929
页数:13
相关论文
共 44 条
  • [21] Lymph node metastases and prognosis in oesophageal carcinoma - A systematic review
    Kayani, B.
    Zacharakis, E.
    Ahmed, K.
    Hanna, G. B.
    [J]. EJSO, 2011, 37 (09): : 747 - 753
  • [22] Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer
    Kelly, Ronan J.
    Ajani, Jaffer A.
    Kuzdzal, Jaroslaw
    Zander, Thomas
    Van Cutsem, Eric
    Piessen, Guillaume
    Mendez, Guillermo
    Feliciano, Josephine
    Motoyama, Satoru
    Lievre, Astrid
    Uronis, Hope
    Elimova, Elena
    Grootscholten, Cecile
    Geboes, Karen
    Zafar, Syed
    Snow, Stephanie
    Ko, Andrew H.
    Feeney, Kynan
    Schenker, Michael
    Kocon, Piotr
    Zhang, Jenny
    Zhu, Lili
    Lei, Ming
    Singh, Prianka
    Kondo, Kaoru
    Cleary, James M.
    Moehler, Markus
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (13) : 1191 - 1203
  • [23] High Density of Tumor-infiltrating B-Lymphocytes and Plasma Cells Signifies Prolonged Overall Survival in Adenocarcinoma of the Esophagogastric Junction
    Knief, Juliana
    Reddemann, Katharina
    Petrova, Ekaterina
    Herhahn, Tobias
    Wellner, Ulrich
    Thorns, Christoph
    [J]. ANTICANCER RESEARCH, 2016, 36 (10) : 5339 - 5345
  • [24] Inhibition of human primary melanoma cell proliferation by histamine is enhanced by interleukin-6
    Lázár-Molnár, E
    Hegyesi, H
    Pállinger, É
    Kovács, P
    Tóth, S
    Fitzsimons, C
    Cricco, G
    Martin, G
    Bergoc, R
    Darvas, Z
    Rivera, ES
    Falus, A
    [J]. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2002, 32 (10) : 743 - 749
  • [25] Mast Cells: Potential Positive and Negative Roles in Tumor Biology
    Marichal, Thomas
    Tsai, Mindy
    Galli, Stephen J.
    [J]. CANCER IMMUNOLOGY RESEARCH, 2013, 1 (05) : 269 - 279
  • [26] The role of surgery in advanced disease for esophageal and junctional cancer
    Monig, Stefan
    van Hootegem, Sander
    Chevallay, Mickael
    Wijnhoven, Bas P. L.
    [J]. BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY, 2018, 36-37 : 91 - 96
  • [27] Mast cells and angiogenesis
    Norrby, K
    [J]. APMIS, 2002, 110 (05) : 355 - 371
  • [28] Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
    Obermannova, R.
    Alsina, M.
    Cervantes, A.
    Leong, T.
    Lordick, F.
    Nilsson, M.
    van Grieken, N. C. T.
    Vogel, A.
    Smyth, E. C.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 (10) : 992 - 1004
  • [29] Tumor eosinophil infiltration and improved survival of colorectal cancer patients: Iowa Women's Health Study
    Prizment, Anna E.
    Vierkant, Robert A.
    Smyrk, Thomas C.
    Tillmans, Lori S.
    Lee, James J.
    Sriramarao, P.
    Nelson, Heather H.
    Lynch, Charles F.
    Thibodeau, Stephen N.
    Church, Timothy R.
    Cerhan, James R.
    Anderson, Kristin E.
    Limburg, Paul J.
    [J]. MODERN PATHOLOGY, 2016, 29 (05) : 516 - 527
  • [30] Sex-specific prognostic effect of CD66b-positive tumor-infiltrating neutrophils (TANs) in gastric and esophageal adenocarcinoma
    Quaas, Alexander
    Pamuk, Aylin
    Klein, Sebastian
    Quantius, Jennifer
    Rehkaemper, Jan
    Barutcu, Atakan G.
    Rueschoff, Josef
    Zander, Thomas
    Gebauer, Florian
    Hillmer, Axel
    Buettner, Reinhard
    Schroeder, Wolfgang
    Bruns, Christiane J.
    Loeser, Heike
    Schoemig-Markiefka, Birgid
    Alakus, Hakan
    [J]. GASTRIC CANCER, 2021, 24 (06) : 1213 - 1226